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Obesity is major health problem today due to its associated complications such as type 2 
diabetes, cardiovascular disease and colon cancer. Among these complications there is 
low grade systemic inflammation, altered gut microbiota as well as an altered 
autonomic regulation of body metabolism. Previous studies have shown that 
bardoxolone methyl (BARD), a compound derived from oleanolic acid, is capable of 
reducing inflammation. This study systematically examined the preventative effects of 
BARD on inflammation in various tissues, including visceral white and brown adipose 
tissues as well as colon tissues, in a chronic high-fat diet induced obesity mouse model. 
Furthermore, this project investigated the effect of BARD on brainstem autonomic 
regulatory centers.  
 
Obesity is characterized by increased fat deposition, enlarged adipocytes and fat masses. 
An overload of energy intake induces an inflammatory response, cell stress and altered 
autonomic function. This study showed that BARD treatment prevents high-fat diet 
induced inflammation. This is evidenced by a prevention of macrophage invasion as 
well as increased pro-inflammatory tumor necrosis factor alpha (TNF-α) and IL-1β in 
visceral fat tissues such as epidydimal and mesenteric fat masses. BARD also prevented 
the high-fat diet induced increase in intracellular signaling molecules associated with 
the inflammatory response, including nuclear factor-kappa light-chain enhancer of 
activated B cells (NF-қB), Akt and ERK, in visceral white adipose tissue. The nervous 
system, including dopamine- peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α), UCP2, and AMP-activated protein kinase (AMPK) 
neuronal signaling, regulates visceral fat mass size. Tyrosine hydroxylase (TH) is a 
biomarker for dopamine production. This study showed that BARD stimulates this 
signaling pathway, from which it prevented excessive deposition of white visceral fat 
induced by a high-fat diet. Interestingly, this study showed that there was virtually no 
desensitisation effect following a chronic BARD treatment. Differing from white 
adipocytes, brown adipocytes promote energy expenditure, which is beneficial for 
obesity. This study showed that BARD stimulated sympathetic regulation of brainstem 




beta 3-adrenergic receptor and PGC-1α signaling. In addition, BARD has anti-
inflammatory effects in brown adipose tissue by promoting the conversion of M1 
(CD11c) to M2 (CD260) macrophages and reducing lipid droplet deposition.  
 
It is known that obesity associated inflammation may be largely due to high-fat diet 
induced alterations in gut microbiota and leaking gut. The colon is extremely important 
in this regard. This study showed that BARD prevented macrophage invasion to the 
colon tissue, which was induced by a high-fat diet. The macrophage biomarker F4/80 
was significantly less in the colon of high-fat diet mice treated with BARD compared 
with vehicle controls. Also, this study found that BARD reduced M1 (CD11) but 
increased M2 (CD260) cells in the colon. Furthermore, we found that BARD prevented 
the high-fat diet induced increase in colonic IL-6, IL-1β and TNF-α. Furthermore, this 
study suggests that BARD may have anti-colon cancer properties as the mice treated 
with BARD had reduced cyclooxygenase 2 protein, increased IL-10, reduced Ki67 as 
well as reduced colon thickness, increased colon crypt depth and number of goblet cells 
per crypt.  
 
In summary, this mechanistic study examining the effects of BARD in chronic high-fat 
diet induced obesity has shown that BARD has a number of beneficial effects to 
visceral white adipose tissues, brown adipose tissues, brainstem and colon tissues and 
may be a good candidate drug for combating obesity. This research, particularly, is 
leading to new insights of BARD in prevention of inflammation and obesity, as 
inflammation is one of the culprits causing obesity complications. However, an animal 
study will never be able to replace a human study. Even then, a thorough toxicity study 
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CHAPTER ONE  
1.1 INTRODUCTION 
There is a growing health crisis from obesity, which contributes to the progression of 
serious disease including gastrointestinal disorders and certain cancers (Pischon et al., 
2008). The obese state is characterised by reduced energy expenditure, deposition of fat, 
chronic low-grade inflammation, oxidative stress and tissue damage (Peng et al., 2012, 
Thaler et al., 2012b, Furukawa et al., 2004, Matsuzawa, 2008, Wang et al., 2005, 
Rogers et al., 2009). The micriobiota-gut-brain-adipose tissue axis has been considered 
to play an important role for obesity development (Geurts et al., 2014, Yi and Tschöp, 
2012). Additionally, alterations in tissues including adipose tissues, gut, and brain 
tissue, are involved in obesity and related complications as per disruption of energy 
homeostasis and weight gain (Vijgen et al., 2011, Yu et al., 2006, Surwit et al., 1998, 
Zhang et al., 2014). Bardoxolone methyl (BARD) is a synthetic triterpenoid derived 
from oleanolic acid, and an antioxidant and anti-inflammatory modulator (Gupta and 
Khaira, 2011). This active compound has been found as a potential drug for treatment of 
tissue damage and other conditions in kidney, lung, pancreas and colon (Kulkarni et al., 
2013, Nagaraj et al., 2010, Pergola et al., 2011a). A suppressive effect of BARD on 
body weight has been observed in obese humans (Manenti et al., 2012). To date the 
preventive effects of BARD on obesity is not well characterised. This project 
investigated the effect of BARD on the prevention of diet-induced obesity, focusing on 
the pathology of the gut-brain-adipose axis. Specifically, a series of studies was 
conducted with an emphasis on understanding the molecular mechanisms of action of 
BARD in the brainstem, colon, epididymal adipose tissue, mesenteric adipose tissue, 




1.2 OVERVIEW OF LITERATURE 
This literature review will describe the rationale for this thesis. The review includes 
obesity prevalence (section 1.2.1), implications of obesity (section 1.2.2), overview of 
synthetic oleanane triterpenoids (section 1.2.3), high-fat diet and obesity (section 1.2.4), 
dietary fat and pathology in colon, brainstem and adipose tissues (section 1.2.5), 
implications for the protective effects of BARD (section 1.2.6), diet-induced obese 
C57BL/6J mouse model for obesity research (section 1.2.7), modulators of energy 
expenditure (section 1.2.8).  
1.2.1 Obesity Prevalence 
The prevalence of overweight and obese individuals has doubled since 1980 and 
continues to increase at an alarming rate. It has been predicted that obesity prevalence 
will increase by 33% in 2030 (Finkelstein et al., 2012), with 3 billion adults becoming 
either overweight or obese by this time (Kelly et al., 2008). For obese individuals, many 
will suffer from type 2 diabetes and there is a 15 to 45% increase in risk of certain 
cancers (Cañete et al., 2007, Pischon et al., 2008). Obesity is also a risk factor for 
cardiovascular disease, for each 5% in weight gain the risk of hypertension increases 
20-30% (Dorresteijn et al., 2012). Risk of death is increased by 20-40% among 
overweight people, and for obese individuals the risk increases 2 to 3-fold (Adams et 
al., 2006). There was up to 3.4 million cases of obesity related death in 2010 (Lim et al., 
2012).  
Many approaches have been used to treat obesity through inducing body weight loss; 
however, there are several limitations in the current treatment of obesity. In the clinic, 
restriction of dietary fat along with physical activity induces insignificant changes in 




body weight regain after treatment among obese patients (Weiss et al., 2007, Van Dale 
et al., 1990). The problem of obesity would benefit from better prevention strategies 
from therapeutic drugs. 
1.2.2 Implications of Obesity 
Key elements in the development of obesity are shown in Figure 1.1. External stimuli 
such as high-fat diet (HFD) induce oxidative stress in white adipose tissue (WAT) 
leading to deposition of fat in WAT and many other peripheral tissues. The production 
of inflammatory cytokines from excess fat disturbs energy homeostasis, resulting in 
reduced energy expenditure. All of these factors contribute to obesity development, 











1.2.3 Overview of Synthetic Oleanane Triterpenoids 
Triterpenes comprise a group of isopentenyl pyrophosphate oligomers with more 
than 20,000 members found in plant roots, leaves, and fruits. These active compounds 




are known as Nrf2 activators, which induce cytoprotective functions via regulating a 
variety transcription factors (Liby et al., 2005, Loboda et al., 2012). The anti-
inflammatory effect of oleanolic acid was first recognised in carrageenan-induced paw 
edema and formaldehyde-induced arthritis in rat (Gupta et al., 1969). Based upon the 
structure of oleanolic acid, to date several hundred synthetic triterpenoids have been 
generated to increase the bioactivity and protective effects of this compound (Dinkova-
Kostova et al., 2005). Synthetic oleanane triterpenoids are potent Nrf2 activators, which 
can protect many organs (gastrointestinal tract, liver, brain) against a variety of diseases 
driven by inflammatory or oxidative stress (Lee et al., 2005). BARD is a synthetic 
oleanolic acid derivative (RTA 402, 2-cyano-3,12-dioxooleane-1,9(11)-dien-28-oic acid 
methyl ester, or CDDO-Me) and was first generated in Gribble’s lab. Figure 1.2 
describes the synthetic modification of BARD from oleanolic acid, where double bonds 
are conjugated to the ketone, providing enhanced biological activity against oxidative 
stress (Sporn et al. 2011). Compared with natural oleanolic acid compound, BARD is 
1000 times more potent in inhibiting the synthesis of inducible nitric oxide synthase.  
 
Figure 1.2. Bardoxolone methyl is a derivative of oleanolic acid 
1.2.3.1 Body Weight Gain and Fat Deposition 
Obese subjects are characterised by excessive body weight and body fat (Trayhurn 




assess obesity, with individuals classified as either normal (BMI ≤ 24.9), overweight 
(BMI = 25-29.9) or obese (BMI ≥ 30). The excessive accumulation of fat in obesity 
leads to fat deposition in multiple tissues. In adipose tissue, deposition of fat is related 
to morphological changes in adipocytes, which plays a central role in metabolic 
syndrome (Bergman et al., 2001). According to National Heart, Lung, and Blood 
Institute/American Heart Association, metabolic syndrome is a cluster of metabolic 
complications including excessive abdominal fat, high blood pressure, high serum 
triglycerides, low good cholesterol (HDL), elevated fasting glucose level and is 
associated with other health problems such as cardiovascular disease and diabetes. The 
increase of adipocyte size in obesity is linked with metabolic syndrome, such as insulin 
resistance in adipose cells (Stern et al., 1972). A greater proportion of enlarged 
adipocytes results in excessive production of inflammatory biomarkers (pro-
inflammatory cytokines) in local adipose tissues (Gustafson et al., 2007, Skurk et al., 
2007). In obese humans, increased adipocyte size correlates with metabolic syndrome 
and type 2 diabetes (Stern et al., 1972, Salans et al., 1968, Krotkiewski et al., 1983). The 
deposition of white fat has been found in brown adipose tissue and the gut of diet-
induced obese rodents (Ghorbani et al., 1997, Sampey et al., 2011, Douglass et al., 
2012). These changes relate to inflammation and oxidative stress in the tissue leading to 
failure in cellular homeostasis and metabolic dysregulation. 
1.2.3.2 Obesity and Inflammation 
Obesity is characterised by low grade inflammation in the circulation and local 
tissues, which is an interplay between obesity and metabolic syndrome (Alemany, 
2013). Modulators of inflammation in obesity include immune cells (macrophages), 






Obesity is associated with WAT remodelling, extensive infiltration of macrophages, 
and changes in the composition of resident immune cells, i.e. the M1 macrophage 
subtype became dominant over the M2 (Strissel et al., 2007). M1 and M2 macrophage 
subtypes differ in function, cell surface marker expression and cytokine profiles. The 
M1 subtype promotes an inflammatory state required when combating infection, 
whereas M2 macrophages promote a proangiogenic environment and are described as 
‘wound healing’ macrophages. Infiltrating macrophages block insulin activity in 
adipocytes (Lumeng et al., 2007b). Macrophage interactions have been observed in 
endothelium and lipid-rich tissues (Lumeng et al., 2007a, Allison et al., 1988, Herrero et 
al., 2010). Interestingly, one study has observed infiltrating macrophages in of HFD-fed 
mice (Sampey et al., 2011). 
1.2.3.2.2 NF-қB and Pro-Inflammatory Cytokines 
Obesity induces inflammation in multiple tissues, demonstrated by increased nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) activity and pro-
inflammatory cytokines, including tumour necrosis factor alpha (TNF-α), interleukin 1 
beta (IL-1β) (Osborn and Olefsky, 2012, Thaler et al., 2012a). Pro-inflammatory 
cytokines decrease insulin sensitivity in adipocytes and contribute to systemic insulin 
resistance, glucose intolerance and type 2 diabetes. Adipocytokines are secreted by 
adipocytes and are predominantly TNF-α and IL-1β, and to a lesser extent IL-6 (Fried et 
al., 1998). The overexpression of IL-6 is associated with carcinogenesis in liver and 




1.2.3.3 Obesity and Oxidative Stress 
It is known that oxidative stress is involved in the pathological process in obesity. 
Particularly, obesity may result in systemic oxidative stress, which in turn induces 
irregular production of adipokines and evokes metabolic syndrome (Esposito et al., 
2006). Oxidative stress can destroy cartilage and cause inflammation. In obese mice, an 
early signature of obesity-associated metabolic syndrome is characterised by elevated 
oxidative stress in accumulated fat, but not liver and muscle (Furukawa et al., 2004, 
Nickelson et al., 2012). Obese humans have greater level of oxidative fat energy 
compared with healthy, non-obese individuals (Astrup et al., 1994). Obesity is 
associated with enhanced expression of stress-activated molecules including signal 
transducer and activator of transcription 3 (STAT3), protein kinase B (Akt), 
extracellular-signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in 
visceral fat, which reduces adiponectin and increases the production of pro-
inflammatory cytokines (Bashan et al., 2007, Chen et al., 2009, Lo et al., 1996). Early 
suppression of oxidative stress in accumulated fat may inhibit metabolic syndrome and 
the progression of obesity-associated complications.   
1.2.4 High-Fat Diet and Obesity 
Overfeeding has been identified as a causative factor for weight gain and obesity in 
humans (Diaz et al., 1992, Tremblay et al., 1992).  In a human study, “The jayhawk 
observed eating trial”,  a diet with >35% energy as fat is classified as a HFD which 
promotes body weight gain in both men and women (Donnelly et al., 2008). In a report 
from Bray and Popkin (1998), around 40% of the total energy consumed by western 
populations is represented by lipids, which correlates to high proportion of  overweight 




Figure 1.3 The correlation between energy intake from fat and overweight 
individuals  
  
1.2.5 Dietary Fat and Pathology in Colon, Brainstem and Adipose Tissues 
HFD changes multiple biochemical and physiological parameters in obesity. 
Alterations have been observed in many organs including the WAT, brown adipose 
tissue, brain and colon.  
1.2.5.1 Epididymal Adipose Tissue and Pathology in Obesity 
Epididymal adipose tissue is the most frequently examined visceral fat in research 
due to its accessibility in rodents (Okuda, 1975, Kim and Park, 2008). Diet-induced 
obese mice have increased expression of total F4/80 macrophage phenotype in 
epididymal adipose tissue (Weisberg et al., 2006, Xu et al., 2003). F4/80 macrophages 
are the typical infiltrating cells found in epididymal adipose tissue of obese mice, and is 
correlated with adipocyte enlargement and excess body mass (Weisberg et al., 2003). In 
addition, cells expressing the macrophage CD11c marker are important producers of 




adipose tissue (Lumeng et al., 2007a). Reduction of mitochondrial uncoupling (ie 
UCP2) has been observed in epididymal adipose tissue of diet-induced obese mice 
(Surwit et al., 1998). 
1.2.5.2 Mesenteric Adipose Tissue and Pathology in Obesity 
Distribution of visceral fat is a key parameter of metabolic syndrome (Park and Lee, 
2005). Compared with other fat depots, mesenteric adipose tissue has higher metabolic 
activity, and is implicated in metabolic syndrome and inflammatory bowel diseases 
(Drouet et al., 2012, Caesar et al., 2010, Desreumaux et al., 1999b). In diet-induced 
obese mice, excess mesenteric fat produces high level of pro-inflammatory cytokines, 
and becomes infiltrated with immune cells (Yu et al., 2006). Inflammation in mesenteric 
fat may shift to other tissues (i.e. liver and colon) causing inflammation in local tissues 
and tumorigenesis (Davies et al., 2013). Moreover, accumulated mesenteric fat is key 
component of Crohn’s disease and colon cancer through the development of creeping 
fat surrounding the gut, which stimulates the production of pro-inflammatory cytokines 
and a strong inflammatory response (Desreumaux et al., 1999a, Peyrin-Biroulet et al., 
2007, Mustain et al., 2013, Arsenescu et al., 2006). With the involvement of mesenteric 
adipose tissue in metabolic syndrome, a strategy to suppress the inflammatory process 
in this tissue may be useful for preventing obesity-associated complications.   
1.2.5.3 Brown Adipose Tissue and Pathology in Obesity 
Brown adipose tissue has been identified as a tissue target for the defence against 
obesity in humans (Ginter and Simko, 2012, Yoneshiro et al., 2013). Brown adipose 
tissue produces thermogenin (UCP1), which generates heat via adaptive thermogenesis 
(Cannon and Nedergaard, 2004). Human infants contain high proportion of active 




found in rodents (Lidell et al., 2013). Recent findings demonstrating the presence of 
brown adipose tissue in adults (van Marken Lichtenbelt et al., 2009, Nedergaard et al., 
2007, Cypess et al., 2009, Virtanen et al., 2009), suggests that human brown adipose 
tissue may contribute to whole body energy metabolism. A human study on healthy and 
obese men has shown that brown adipose tissue activity is correlated with body weight 
and body fat mass (van Marken Lichtenbelt et al., 2009), in which obese individuals 
have lower brown adipose tissue activity (Vijgen et al., 2011). In obese individuals, 
brown adipose tissue becomes inactivated as assessed by reduced energy expenditure or 
resting metabolic rate and reduced UCP1 (van Marken Lichtenbelt et al., 2009). WAT-
like brown adipocytes develop in brown adipose tissue of mice fed with a HFD, which 
is associated with fat deposition, loss of mitochondria, and macrophage invasion in this 
tissue (Sampey et al., 2011). HFD reduces UCP1 and thermogenic capacity in brown 
adipose tissue (Vitali et al., 2012). It also leads to mitochondrial dysfunction  in brown 
adipose tissue, resulting in low oxygen consumption and reduced thermogenic capacity 
of brown adipose tissue and obesity (Himms-Hagen and Desautels, 1978, Himms-
Hagen, 1989).  
1.2.5.4 Brainstem and Pathology in Obesity 
The brainstem is an autonomic centre for the control of energy expenditure. 
Brainstem regions, including dorsal vagal complex (DVC) and ventrolateral medulla 
(VLM), are involved in the regulation of energy expenditure and promote heat 
production. The VLM maintains sympathetic vasomotor and arterial pressure via rostral 
nuclei (Spyer, 1994). Tyrosine hydroxylase (TH) is expressed by catecholaminergic 
nucleus tractus solitarius (NTS) neurons in the brainstem DVC that deliver the signals 




in the brainstem has been observed in obese rat models (Zhang et al., 2014). 
Improvement of brainstem function may help in preventing obesity.   
1.2.5.5 Colon and Pathology in Obesity 
WAT secretes pro-inflammatory cytokines, and overexpression of these markers 
provokes inflammation within WAT which could also affect neighbouring tissues  (liver 
and colon), causing local inflammation (Stanton et al., 2011). Obesity also results in 
chronic low grade inflammation and increased inflammatory processes in the colon 
(Rubin et al., 2012, Terzić et al., 2010, Itzkowitz and Yio, 2004). Quiescent 
inflammation in colon is associated with progressive invasion of immune cells (Atreya 
and Neurath, 2008); and macrophages infiltrate the colon during inflammatory and 
carcinogenic progression (Funada et al., 2003). HFD promotes the development of 
colon tumours and cancer in colon cancer mouse models (Tuominen et al., 2013). A 
study of 156,730 people has demonstrated the link between increased body mass and 
the risk of colon cancer  (Morikawa et al., 2013). Although chronic inflammation is 
considered as a key contributor to the development of colon cancer, the importance of 
colon inflammation in diet-induced obesity is not yet clear. 
1.2.6 Implications for Protective Effects of BARD 
Synthetic oleanolic acid analogues including BARD act as Nrf2 activators and NF-
kB inhibitors, making them potentially useful for the treatment of disease with an 
inflammatory component, such as neuro-degenerative disorders and cancers (Stack et 
al., 2010).  
Many studies have been conducted to investigate the health benefits of BARD, 
demonstrating BARD effects in the prevention and treatment of disease. BARD blocks 




activated mouse macrophages (Sporn et al., 2011, Honda et al., 2002). It inhibits the 
inflammatory response (IκBα kinase/NF-κB signalling) in various tumour cells 
(Shishodia et al., 2006). Several studies have indicated that BARD may be beneficial in 
treating obesity. Oral BARD reduced body fat mass in diet-induced obese mice (Saha et 
al., 2010). In human studies, oral BARD supplementation induces body weight loss in 
obese individuals (Manenti et al., 2012). A summary of relevant studies of BARD is 
shown in Table 1.1. These studies have shown the following pharmacological properties 
of BARD: (1) Induction of Nrf2 signalling molecules, suggesting a cytoprotective role 
in many organs (2) Suppression of cancer cells, suggesting therapeutic effects in cancers 
(3) Induction of weight loss in obese humans suggesting an anti-obesity effect (4) A 
side effect of heart failure has been observed in advanced chronic kidney disease and 
heart disease patients, suggesting BARD should not be used in individuals with a risk of 
heart failure.  
Preclinical studies have demonstrated that BARD has effective concentration in body 
which is well-tolerated and suitable for daily oral administration. In non-human 
primates, all forms of BARD have high bioavailability, with plasma concentrations 
from 4 to above 7 ng/mL found in cynomolgus monkeys after 24 hours administration 
at 10mg/kg body weight (Walling et al., 2012). Oral administration of BARD for 28 
days (30mg/kg) or 12 months (5, 30, 300mg/kg dose) improved kidney functions in 
cynomolgus monkeys without adverse effects (Reisman et al., 2012). In rodent, 
intratumor level of BARD (7.5 mg/kg dose) in 4T1 breast cancer bearing mice was 
above 3µmol/L which is much higher than its concentration (500 nmol/L) for growth-
inhibitory effects in 4T1 breast cancer cells in vitro (Ling et al., 2007).  
BARD is a potent, orally bioavailable Nrf-2 agonist, which is known to regulate up 




potential of BARD for the treatment of disease is well recognised, however there is little 
information on the effect of this compound in obesity-associated pathology in specific 
tissues. Although treatment studies in mice and humans have demonstrated anti-obesity 
effects of BARD, the molecular mechanisms in humans are not clear and those in diet-
induced obese animal models are still under investigation. This PhD project was 
designed to investigate the biochemical effects of oral BARD in diet-induced obesity in 
mice. In the body, BARD distributes widely from the gut to the brain (Yates et al., 
2007), suggesting multifactorial effects across tissues. I investigated BARD effects on 
tissue pathologies by determining tissue morphology and many biomarkers expressing 
inflammation, oxidative stress, energy expenditure in epididymal adipose tissue in 
Chapter 2, mesenteric adipose tissue in Chapter 3, brown adipose tissue and the 
brainstem in Chapter 4 and colon in Chapter 5. 
Interestingly, BARD treatment induces a 10% increase in oxygen consumption in 
HFD mice, indicating a thermogenic property of this compound (Saha et al., 2010). In 
humans, brown adipose tissue has high mitochondrial activity, with oxygen 
consumption 300% higher than subcutaneous fat (Vijgen et al., 2013). Brown adipose 
tissue, WAT and the brainstem are known to be involved in energy homeostasis (section 
1.2.5 and 1.2.8). An interesting question addressed by this PhD project was, whether 
effects on brown adipose tissue are the key element for BARD improving energy 
expenditure or if the WAT and the brainstem are also involved. This thesis discusses the 
effect of BARD on the expression of energy expenditure proteins across WAT, brown 






Table 1.1  List of studies using BARD in disease treatment 




antitumor activity in 
patients with 
advanced solid 
tumour or lymphoid 
malignancy (2006-
2008) 
Expressing grade 3 
reversible liver 
transaminase 
elevations, 900 mg/day 
as the maximum 
tolerated dose, reduced 
NF-κB and cyclin D1 
in tumour biopsies. 
Phase 1 clinical trial, 
completed 
(Hong et al., 2012) 
BARD effects on 
kidney function in 
advanced CKD and 





and tissue damage. 
Phase 2 clinical trial, 
completed 
(Pergola et al., 
2011a) 
BEAM study (2010) 
Increase in renal 
eGFR, and weight 
reduction after 24 
weeks of treatment. 
Phase 2 clinical trial, 
completed 
(Pergola et al., 
2011b) 
Progression to end 
stage renal disease or 
cardiovascular death 
in patients with 
Stage 4 CKD 
BEACON study 
(2011-2012) 
Heart failure side 
effects 




Weight loss study in 
obese patients  
Weight loss for up to 
52 weeks at 150mg 
once daily 
Human study 



















Phase 1 clinical trial, 
completed 








suppressor cells and 
improved immune 
response  
In vivo (Nagaraj et al., 2010) 
Treatment of lung 


















stress in colonic 
epithelial cells 
Protects colonic 
epithelial cells from 
ionizing radiation-
induced damage 
In vitro (Kim et al., 2012b) 
Treatment of lung 
cancer in mice 
BARD (10mg/kg body 
weight) in diet reduced 
tumours, inhibited 
proliferation of mouse 
lung carcinoma cells 
and reduced 
inflammation 
In vivo (Liby et al., 2009) 
Treatment of diet-
induced obese mice 
BARD (3 mg/kg body 
weight) via oral 
gavage reduced pro-
inflammatory 
cytokines, total body 
fat, activated AMP-
activated protein 
kinase in muscle and 
liver, and increased 
oxygen consumption 
In vivo (Saha et al., 2010) 
Treatment of colitis-
associated colon 
cancer in mice 
Reduced tumours, 




In vivo (Choi et al., 2014) 
Prevention of breast 
cancer in mice 
Delayed tumour 
development 









In vivo (Auletta et al., 2010) 
Anti-inflammation in 
murine BV2 









In vitro (Tran et al., 2008) 
Prevention of murine 




signalling and reduced 
nephritis expression of 
Akt/ERK/NF-κB 
signalling 
In vivo (Wu et al., 2014) 
Apoptosis-inducing 
activity of BARD in 
human prostate 
cancer cell lines 
 Inhibited Akt, NF-κB 
signalling proteins 
In vitro (Deeb et al., 2007) 
Anti-cancer effects 
in ovarian cancer 
cells 
Inhibited the activation 




(Duan et al., 2009, 




Studies Findings Status Reference 
Prevention of 
prostate cancer in 
mice 
BARD (7.5 mg/kg 
body weight) 
treatment for 20 weeks 
inhibited preneoplastic 
lesions 
In vivo (Gao et al., 2011) 
Abbreviations: Akt: protein kinase B; BARD: bardoxolone methyl; BEACON: 
evaluation in patients with chronic kidney disease and type 2 diabetes: the occurrence of 
renal events"; BEAM: treatment: renal function in CKD/Type 2 diabetes; CKD: chronic 
kidney disease;  eGFR: estimated glomerular filtration rate; ERK: extracellular signal-
regulated kinase; IL-6: interleukin-6; LPS: lipopolysaccharides; NF-κB: nuclear factor 
kappa-light-chain-enhancer of activated B cells; STAT3: signal transducer and activator 
of transcription 3.  
1.2.7 Diet-Induced Obese C57BL/6J Mouse Model for Obesity Research 
Most rodents (rats and mice) become obese when fed with a HFD, and have been 
used to mimic obesity in humans (Hariri and Thibault, 2010). HFD induced obese 
C57BL/6J mice are an important and relevant animal model for obesity research. It has 
been confirmed that C57BL/6J mice on HFD become obese compared to those on a 
normal diet (West et al., 1992). Similar to humans consuming a western-diet, C57BL/6J 
mice have excessive body weight gain when maintained on diets containing 30-45% 
energy from fat (de Wit et al., 2011). Compared to other mouse strains, C57BL/6J mice 
are more susceptible to obesity when fed a HFD (Rossmeisl et al., 2003, Sims et al., 
2013). Moreover, HFD mice develop metabolic syndrome resembling that in obese 
humans, involving insulin resistance, glucose intolerance, hyperglycaemia, and 
inflammation (Surwit et al., 1995). Many studies have used C57BL/6J mice in obesity 
research and new drug development (Ahrén and Pacini, 2002, Lin et al., 2000, Huang et 
al., 2011). 
Diet-induced obese C57BL/6J mice have features useful for research on obesity-
associated pathogenesis. Similar to obese humans, reduced energy expenditure has been 
shown in diet induced obese C57BL/6J mice, involving reduction of energy expenditure 




tissue compared with obesity-resistant Sv129 mice (Vitali et al., 2012). In another 
study, male C57BL/6 mice on a HFD containing 45% energy from fat for 20 weeks 
became obese, developed insulin resistance, and developed inflammation of WAT 
(infiltration of F4/80 and CD11c macrophages and pro-inflammatory cytokines in 
WAT) (Lumeng et al., 2007a). TNF-α and IL-1β mRNA was upregulated in epididymal 
and mesenteric adipose tissue when C57BL/6J male mice were on HFD for 6, 16, and 
26 weeks (Stanton et al., 2011). Furthermore, evidence of HFD-induced gut 
inflammation has been found in C57BL/6J mice (Shen et al., 2014). Examining the 
effect of BARD in diet-induced obese C57BL/6J mice may help understand the 
mechanism by which it prevents obesity.  
Several studies have demonstrated the therapeutic effects of pentacyclic triterpenes 
and their analogues in the treatment of obesity in HFD-fed C57BL/6J mice including 
BARD (Chin et al., 2013, Saha et al., 2010). Diet-induced obese C57BL/6J mice have 
also been successfully used for the research of anti-obesity drugs in our lab (Yu et al., 
2013). Therefore, in this project we used the inbred mouse C57BL/6J strain on a HFD 
(40% energy from fat), to investigate the preventive effects of BARD on diet-induced 
obesity.  
1.2.8 Modulators of Energy Expenditure  
Weight gain is caused by elevated positive energy balance, where high energy intake 
from food reduces energy expenditure leading to overweight and obese (Ravussin et al., 
1988, Lazzer et al., 2003). A cohort study has identified that a 150 kcal/day reduction in 
positive energy balance could prevent excess body weight gain in children (Wang et al., 
2006). Physical activity to increase energy expenditure and energy restricted diets to 
reduce energy intake have been used as weight loss strategies (Barte et al., 2010).  




2007, Byrne et al., 2004, Clapham, 2004). Alternatively, efforts have been made to 
increase energy expenditure through dietary and pharmacological intervention (Brehm 
et al., 2005, Clapham, 2004, Rao et al., 2011). Biomarkers involved in the control of 
energy expenditure process include TH, PGC-1α, UCP1, UCP2, β3-AR, and AMPK. 
Some of these molecules act in the central-peripheral network controlling whole body 
energy homeostasis. 
1.2.8.1 PGC-1α 
Animal studies have demonstrated peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α) is a key regulator of mitochondrial biogenesis in mice and 
required for adaptive thermogenesis (Puigserver et al., 1998, Leone et al., 2005). In 
adipose tissue, PGC-1α is also a key regulator of mitochondrial biogenesis, since the 
increase of this gene in brown adipose tissue and WAT results in upregulation of 
thermogenesis, and reduction of body weight and fat mass (Lelliott et al., 2006). A 
study in young chickens observed mitochondrial biogenesis in vertebrate peripheral 
neurons, proposed as occuring by exclusive replication and division of mitochondria in 
axons (Amiri and Hollenbeck, 2008). It has been shown that PGC-1α is inducible in 
most tissues in response to calcium and cyclic AMP signalling (St-Pierre et al., 2006).  
1.2.8.2 Uncoupling Proteins 
Mitochondria are involved in energy homeostasis. Induction of mitochondrial 
uncoupling in WAT and brown adipose tissue eliminates obesity (Medina-Gómez, 
2012, Kopecky et al., 1995). UCP1 induces energy dissipation through basal proton 
conductance in brown adipose tissue mitochondria (Parker et al., 2009). UCP2 is a 
homologue of UCP1, and may function similarly to UCP1 to dissipate energy. UCP1 




energy (Enerback et al., 1997). Moreover, a report has implicated UCP2 in regulating 
thermogenesis, energy expenditure and body weight (Gimeno et al., 1997). Specifically, 
UCP2 contributes to the partial coupling of respiration to ADP phosphorylation in the 
mitochondria (Viguerie-Bascands et al., 1999). UCP2 presents in WAT, and HFD 
increases UCP2 mRNA expression in WAT of obesity-resistant A/J and C57BL KsJ 
mice but not in obesity-prone C57BL6J mice (Surwit et al., 1998). In addition to the 
WAT, expression of UCP2 mRNA and protein has been observed in various regions of 
nonhuman primate brain including hypothalamus and the brainstem, suggesting its 
involvement in central autonomic, endocrine and metabolic regulation (Diano et al., 
2000).    
1.2.8.3 β3-AR 
β3-adrenergic receptor (β3-AR) participates in fat deposition and the induction of 
energy expenditure (Collins, 2012). A rat study has shown that WAT including 
epididymal and mesenteric adipose tissue are innervated by adrenergic nerves (Slavin 
and Ballard, 1978). In humans β3-AR exists in both brown adipose tissue and WAT, and 
is involved in the sympathetic control of body fat mass through utilization of fat stores 
and lipid assimilation during meals (Krief et al., 1993). C57BL/6J ob/ob mice have a 
significant reduction of β3-AR protein in both WAT and brown adipose tissue compared 
with lean mice (Collins et al., 1994). The activation of β3-AR signalling increases 
thermogenesis and resistance to obesity (Bachman et al., 2002). Daily injection of β3-
adrenergic agonist in obese mice increases mitochondrial uncoupling in mesenteric fat, 
which is accompanied by reduced body weight and fat mass, and reduced lipid droplets 
in brown adipocytes (Nagase et al., 1996). Administration of β3-AR agonist activates 
energy expenditure in WAT and brown adipose tissue (Grujic et al., 1997) and 




2008). Therefore, activation of β3-AR in adipose tissues would be a beneficial property 
of potential anti-obesity drugs. 
1.2.8.4 Tyrosine Hydroxylases 
Tyrosine hydroxylase (TH) is a rate limiting enzyme involved in the synthesis of 
catecholamine that induces thermogenesis and energy expenditure. TH activation results 
from nerve stimulation, and is a marker for noradrenergic nerve fibres (Morgenroth et 
al., 1974, Nagatsu, 1995). Noradrenergic neurons are involved in the control of 
thermogenic activity of brown adipocytes (De Matteis et al., 1998). Particularly, 
efferent visceral neurons from the brain directly contact with adipocytes through 
noradrenergic parenchymal fibres, which activates adipocytes via adrenergic receptors 
(Jacobsson et al., 1986). Cold acclimation in mice has shown that increased 
noradrenergic parenchymal fibres are correlated with brown adipocyte density (Murano 
et al., 2009). Since noradrenergic activation can induce mobilisation of lipid in brown 
adipose tissue and WAT, in this project I investigated whether BARD can target TH in 
multiple adipose tissue depots including epididymal adipose tissue, mesenteric adipose 
tissue, brown adipose tissue and whether brainstem DVC or VLM are centres for the 
delivery of noradrenergic parenchymal fibres. The upregulation of TH activity would be 
a novel target for the increased energy expenditure effects of BARD.  
1.2.8.5 AMPK 
 
AMPK is a heterotrimeric protein with an α1-subunit isoform, which is dominantly 
expressed in WAT and controls energy expenditure (Flachs et al., 2013). In WAT, 
AMPK activation suppresses ATP consumption and stimulates the generation of ATP 
from various processes such as mitochondrial biogenesis and glucose uptake (Klaus et 




pathways that produce ATP while switching off anabolic pathways that consume ATP. 
Moreover, AMPK regulates genes involved in energy metabolism such as mitochondrial 
uncoupling, mitochondrial biogenesis (PGC-1α) and SIRT1 activity related proteins 
(Canto et al., 2009, Matejkova et al., 2004, Cantó and Auwerx, 2009). 
1.2.8.6 Neural Control of Energy Expenditure 
Studies on rats and Syrian hamsters have indicated the brainstem as the centre for the 
sympathetic outflow to WAT and brown adipose tissue (Bamshad et al., 1998, Bamshad 
et al., 1999). Hindbrain or brainstem contains dorsal vagal complex (DVC) and 
ventrolateral medulla (VLM) regions involved in the control of energy balance and 
energy expenditure (Grill and Hayes, 2012). Neurons from the DVC control 
parasympathetic outflow to visceral organs; particularly, the solitary tract (NTS) in the 
DVC receives and integrates energy status signals including those from peripheral 
organs (Pagani et al., 1985). Moreover, output from caudal NTS neurons in cooperation 
with those from the VLM neurons project to the spinal cord, which controls sympathetic 
responses for energy expenditure (Grill, 2006). A previous study has shown that VLM 
has a synaptic link with brown adipose tissue (Madden et al., 2013), suggesting 
sympathetic outflow from the brainstem to brown fat. These reports demonstrate the 
importance of the brainstem in sympathetic signalling to the WAT and brown adipose 
tissue.   
1.3  AIMS 
1.3.1 Hypotheses  
 The research determines the anti-obesity effects BARD on the gut-brain-adipose of 




induced pathology in WAT including epididymal and mesenteric adipose tissue, in 
brown adipose tissue and the brainstem, and in colon. 
1.3.2 General Aims 
This project investigated the therapeutic effects of BARD on the prevention of 
obesity associated pathology in tissues including brainstem, colon, epididymal adipose 
tissue, mesenteric adipose tissue and BAT. Elucidation of the molecular mechanisms of 
action on inflammation, oxidative stress, and energy expenditure within these local 
tissues were a priority of the project. 
1.3.3 Specific Aims 
1 The specific aims of this project were:  To investigate the effects of BARD on 
pathology in epididymal adipose tissue. The project aims to determine the level of 
tissue inflammation through the expression of adipocyte size (fat deposition) and 
pro-inflammatory cytokines. The research further determines BARD effects on the 
expression of total stress-activated proteins. Finally, the proposed research 
determines energy regulation through the expression of energy expenditure proteins. 
2 To investigate the effects of BARD on pathology in mesenteric adipose tissue. First 
experiment is to determine inflammatory level through the expression of mesenteric 
adipocyte size, crown-like structures, M1/M2 macrophages and pro-inflammatory 
cytokines. Additional aims are to determine the activation of stress-activated proteins 
and the expression of energy expenditure proteins. 
3 Brown adipose tissue and the brainstem, which are known as therapeutic targets in 
human obesity due to the intact sympathetic innervation and anti-obesity effects, are 
included in the third aim of this research: Firstly, to determine BARD ability in 




area and droplets, crown-like structures, M1/M2 macrophages. Furthermore, to 
determine whether the ability of BARD in enhancing sympathetic activity in brown 
adipose tissue and the brainstem DVC and VLM by measuring the expression of TH 
activity and other energy expenditure proteins. 
4 Final aim of the research is to investigate the effects of BARD on pathology in colon. 
The research focuses on colon inflammation through the expression of colon 
morphology, macrophages, NF-қB, pro-inflammatory cytokines, Ki67, Cox2 and 
fecal microbiota. 
1.3.4 Significance 
Obesity has become an epidemic, with millions of obesity related deaths every year. 
The increased body weight and development of obesity in humans results from an 
adaption to HFD. The current literature review has demonstrated multiple biochemical 
mechanisms contributing to obesity-associated pathology within the gut-brain-adipose 
axis. These include the enlargement of adipocytes, progression of inflammation and 
oxidative stress, and reduction of energy expenditure. Strategies to suppress body 
weight and biochemical changes in these tissues may help to prevent the development 
of obesity due to the effects of HFD.  
Reports have demonstrated the potential of BARD in the treatment of numerous 
diseases. However, its preventive effects on obesity and associated pathology within 
tissues of gut-brain-adipose axis have not been established. This project will provide a 
scientific evidence for the biochemical effects of BARD on tissue pathology in 
epididymal fat, mesenteric fat, brown fat, colon and the brainstem, and provide 




1.4 GENERAL METHODS 
1.4.1 Ethic Statement 
All animal procedures were approved by the Animal Ethics Committee, University 
of Wollongong (Permission number: AE12/15), and were in accordance with the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes 
(ACPC UASP). All efforts were made to minimise animal stress. 
1.4.2 Animal Procedures and Dietary Treatments 
Male C57BL/6J mice (12 weeks age), were obtained from the Animal Resource 
Centre, Perth, Western Australia. All mice were housed in environmentally controlled 
conditions, temperature (22 ºC) and light/dark (12/12 h) cycle. One week after arrival, 
the mice were randomly divided into three experimental groups (n = 7) and received 
either feeding of normal diet (LFD group), a HFD (HFD group), or a HFD 
supplemented with BARD in drinking water (HFD/BARD group). The % of calories 
from fat/protein/carbohydrates in the HFD and normal diet are 40:15:45 and 5:18:77, 
respectively. The dose of BARD was 10mg/kg body weight in accordance previous 
studies, shown to induce an anti-inflammatory and anti-cancer effect in mouse models 
(Liby et al., 2009, Wu et al., 2014). Moreover, 10mg/kg dose of BARD and its analog 
(RTA405) has been shown to be well-tolerated and efficacious in non-human primates 
(monkeys), HFD-fed C57BL/6 mice and diabetic rat model (Walling et al., 2012, Chin 
et al., 2013). To prevent any effects on the palatability of the diet, BARD was 
administered in daily drinking water instead of directly added to the diet. The 
preparation of drinking water with BARD was based on a previous report, which 
prepared an oral pentacylic triterpene (ursolic acid) for obesity intervention in HFD-fed 




Tween 80 (at a concentration of 1.9 mg/ml). The stock was then dissolved in drinking 
water (at a concentration of 38mg/L) which provides a dose of 10mg/kg body weight in 
mice based on daily water consumption.  
The proposed intervention was conducted for 21 weeks which is a required duration 
to observe HFD-induced inflammation in multiple tissues including intestinal organs as 
per previous reference (Axling et al., 2012). Previously, early intervention with BARD 
for 20 weeks effectively prevented the progression of preneoplastic lesions to 
adenocarcinoma in the transgenic adenocarinoma of the mouse prostate (TRAMP) 
model (Gao et al., 2011). In present project, a chronic study is necessary to generate the 
data mimicking obese human conditions since short term study will not be able to 
address questions on HFD-induced inflammation and the preventive effects of BARD. 
BARD (>98% purity) was purchased from Shanghai Haoyuan Chemexpress Co., Ltd 
(CAS: 218600-53-4). 
The design of this study is summarised in Figure 1.4 below.  
 




1.4.3  Euthanasia and Tissue Collection 
At week 21 of the animal procedure, all mice were euthanized by fast CO2 infusion. 
Epididymal adipose tissue, mesenteric adipose tissue, brown adipose tissue, the 
brainstem and colon were collected and treated as per requirement of each experiment.  
Epididymal adipose tissue (Chapter 2), mesenteric adipose tissue (Chapter 3) and 
inter-scapular brown adipose tissue (Chapter 4) were dissected. All tissues were cut into 
two halves: one half was stored in -80 ºC, and another half was fixed by immersing at 
4% paraformaldehyde. The fixed samples were processed for paraffin embedding using 
Leica EG1150H paraffin embedding station (Leica Microsystems, NSW, Australia). 
Embedded blocks of all adipose tissue were cut using Leica RM2255 rotary microtome 
(Leica Microsystems, NSW, Australia) and placed on polylysine slides for histology 
and immunohistochemistry.  
In Chapter 4, entire mouse brain of all mice was immediately removed, and stored in 
-80 ºC for Western blot. Frozen brain sections were cut at 400 µm, which is based on a 
standard mouse brain atlas (Paxinos G. and Franklin KBJ., 2002, Camer et al., 2015), by 
using Leica CM1950 cryostat (Leica Microsystems, NSW, Australia). The two 
brainstem regions including VLM and DVC were collected from sections using a 
Stoelting Brain Punch (#57401, 0.5 mm diameter, Wood Dale, Stoelting Co., IL, USA). 
The samples were then used for examining energy expenditure proteins by Western 
Blot. 
In Chapter 5, entire colon of all mice was collected and washed in phosphate buffer 
saline as described in established study (Whittem et al., 2010). One part of colon was 
kept frozen at -80 ºC for examining fat deposition, while the remaining part of the colon 
was fixed in 4% paraformaldehyde as per previous report (Whittem et al., 2010). The 




adipose tissue. All frozen colons were mounted with optimum cutting temperature 
medium overnight, and cut at 10 μm by cryostat for oil-red O staining. Fecals from all 
mice were also collected and kept frozen at -80 ºC for bacterial quantification. 
1.4.4 Histology 
1.4.4.1 Haematoxylin and Eosin Staining of Adipose Tissues and Colon 
Paraffin-embedded sections of epididymal adipose tissue (Chapter 2), mesenteric 
adipose tissue (Chapter 3), brown adipose tissue (Chapter 4), and colon (Chapter 5) 
were used for histology. All tissue sections were stained with Haematoxylin and Eosin 
(H & E) using a 1 x Linear Stainer (ST4020, Leica Microsystems, NSW, Australia). 
The procedure for staining is described in Table 1.2. Photomicrographs were taken of 
the stained sections, and images quantified using ImageJ 1.46r software. The following 
parameters were quantified in histological images, measurement of adipocyte size and 
number in WAT (Chapter 2 and 3), lipid area and lipid droplet size in brown adipose 
tissue (Chapter 4), and colon crypts and goblet cells in colon (Chapter 5). 
                          Table 1.2 Procedure of H & E staining 
Steps Solutions Time (min) 
Dewaxing Xylene 2 
Dewaxing Xylene 2 
Dehydrating 100% ethanol 2 
Dehydrating 95% ethanol 2 
Nuclear staining Haematoxylin 0.5 
Washing Tap water 2 
Blueing Scott’s tap water 5 
Washing Tap water 2 
Dehydrating 95% ethanol 2 
Cytoplasm staining Eosin 1 
Dehydrating 95% ethanol 2 
Dehydrating 100% ethanol 2 
Dehydrating 100% ethanol 2 
Clearing Xylene 2 




1.4.4.2 Oil-Red O Staining of Neutral Fat in Mouse Colon 
In Chapter 5, sections of frozen colons were fixed with 10% formalin before 
incubating in 100% propylene glycol for 2 min. Sections were then incubated in 0.5% 
oil-red O (Sigma-Aldrich Pty. Ltd, Sydney, NSW, Australia). Stained sections were 
cover-slipped with glycerine jelly for imaging. Oil-red O staining was quantified by 
ImageJ 1.46r software.  
1.4.5 Adipose Tissue and Colon Immunohistochemistry 
Paraffin-embedded sections (n=7 mice per group) of epididymal adipose tissue 
(Chapter 2), mesenteric adipose tissue (Chapter 3), brown adipose tissue (Chapter 4), 
and colon (Chapter 5) were processed for immunostaining with antibodies. The primary 
antibodies used for immunohistochemistry were: F4/80 (ab6640), CD11c (ab33483), 
CD206 (ab64693), IL-10 (ab34843), Ki67 (ab15580) (Abcam Inc, Cambridge, MA); 
NF-қBp65 (sc-109), phosphorylated NF-қBp65 (sc-33020), IL-6 (sc-7920), IL-1β (sc-
7884), TNF-α (sc-8301) (Santa Cruz Biotechnology (Dallas, TX)). Appropriate 
secondary antibodies were used including rat IgG biotinylated secondary antibody 
(ab6733), Armenian hamster IgG H&L biotin (ab5744), and rabbit IgG H&L biotin 
(ab6720) (Abcam Inc, Cambridge, MA). Dilutions of antibodies used for 
immunohistochemistry were tissue dependent: F4/80: 1/150 for adipose tissues, 1/1000 
for colon; CD11c: 1/150 for adipose tissues, 1/500 for colon; CD206: 1/500 for adipose 
tissue, 1/3000 for colon. Colon was stained with TNF-α (1/100), IL-1β (1/100), IL-6 





1.4.6 Western Blot 
The expression of target proteins in epididymal adipose tissue (Chapter 2), 
mesenteric adipose tissue (Chapter 3), brown adipose tissue (Chapter 4) and the 
brainstem (Chapter 4), was detected by Western Blot using previously described 
procedures (Du Bois et al., 2012). The concentration of extracted protein was identified 
by the bicinchoninic acid assay (Pierce Chemical Co., Rockford, IL). The amount of 
protein loaded was 25μg per lane. Horseradish peroxidase conjugated secondary 
antibodies and enhanced chemiluminescence reagent (GE Healthcare, Piscataway, NJ, 
USA) were used to detect proteins of interest. Quantity One software (Bio-Rad) was 
used to quantify the Western blot bands. Detected proteins were normalised to β-actin.  
The primary antibodies used for Western blot were: TNF-α (sc-8301), UCP1(sc-
6529), UCP2 (sc-6525), JNK (sc-571), β3-AR  (sc-1473), Akt1/2/3 (sc-8312), pJNK 
(sc-6254), pAkt1/2/3 (sc-33437), PGC-1α (sc-13067) (Santa Cruz Biotechnology 
(Dallas, TX)); hydroxylase phosphoSer 40 (AB5935), tyrosine hydroxylase (AB9983) 
and Actin (MAB1501) (Merck Millipore (Kilsyth, Victoria, Australia); IκB-α (#9242), 
STAT3 (#4904), ERK1/2 (#4695), pERK1/2 (#4370), pSTAT3 (#9145) (Cell Signalling 
Technology (Beverly, MA)). The secondary antibodies used for Western blot were: goat 
anti-rabbit (AP307P), goat anti-mouse (AP308P) (Chemicon International, Inc. 
(Temecula, CA)), and donkey-anti-goat (sc-2033) (Santa Cruz Biotechnology (Dallas, 
TX). The dilutions for anti-bodies were as follows: 1/200 (TNF-α, IL-1β, IL-6), 1/1000 
(IκB-α, PGC-1α, Akt1/2/3, pAkt, ERK, pERK, JNK, pJNK), 1/500 (UCP1, UCP2, β3-




1.4.7 Quantitative Real-Time PCR (qRT-PCR) of Colon Microbiota 
In Chapter 5, DNA from frozen cecal contents of mice was extracted using the 
ISOLATE DNA kit (Bioline, NSW, Australia). PCR reactions (20 µl) were conducted 
with SensiFast™ SYBR No-ROX reagents (Bioline NSW, Australia) to quantify the 
abundance of dominant bacterial strains, including the Gram-positive Bifidobacterium 
spp., Lactobacillus spp., and the Gram-negative Bacteroides-Prevotella spp. Primers 
were purchased from Sigma-Aldrich Pty. Ltd, Sydney, NSW, Australia. The 16S rDNA 
sequences for forward (F) and reverse (R) primers were Bacteroides-Prevotella, F-
GAGAGGAAGGTCCCCCAC; R-CGCTACTTGGCTGGTTCAG; Lactobacillus, F-
GAGGCAGCAGTAGGGAATCTTC, R-GGCCAGTTACTACCTCTATCCTTCTTC; 
Bifidobacterium, F-CGCGTCTGGTGTGAAAG, R-CCCCACATCCAGCATCCA. The 
PCR conditions were 95 ºC (3 min), followed by 40 cycles of   95 ºC (5 sec), 60 ºC (10 
sec), and 72 ºC (10 sec) using Light cycler 480 real-time PCR system (F. Hoffmann-La 
Roche Ltd, Switzerland). Relative bacterial population was quantified as per Livak’s 
method, with universal primers values as reference (Condezo-Hoyos et al., 2014). 
1.4.8 Statistical Analysis 
The size of animal groups in this project was determined by Joint Medical Program  
software (SAS Institute Inc., Cary, NC, USA). SPSS 19 software (SPSS, Chicago, IL) 
was used for data analysis. Normal distributions of data were determined by the 
Kolmogorov–Smirnov test. A least significant difference (LSD) post-hoc analysis was 
used to determine a significant difference between treatment groups. Pearson’s test was 
used to determine the correlation among immunohistochemistry staining parameters. 




1.5 OVERVIEW OF THESIS 
The prevalence of obesity has reached alarming proportions, and is associated with 
increased risk serious disease and death. Individuals who consume a HFD are more 
susceptible to weight gain and obesity. Fat deposition, reduced energy expenditure 
process, low grade inflammation, and oxidative stress are the series of obesity 
associated events. HFD induces alterations in WAT, brown adipose tissue, colon and 
the brainstem, and targeting of pathologies in these tissues may help to reduce obesity 
associated health risk. Various anti-obesity drugs have been investigated for the 
prevention and treatment of obesity; however, the mechanisms of anti-obesity drugs are 
complex and may have adverse effects. BARD is a promising synthetic oleanolic acid 
for the treatment of chronic diseases due to its potent anti-oxidant and anti-
inflammatory properties. To date the effect of BARD in brain, colon and adipose tissue 
during obesity have not been thoroughly investigated. In this project, I investigated the 
effect of BARD on brainstem-colon-adipose axis in diet-induced obesity. This is a 
preventative study and oral BARD was used to prevent diet-induced obesity in 
C57BL/6J mice.  
1.5.1 BARD Prevents Pathology in Epididymal Adipose Tissue of High-Fat Diet-
Fed Mice 
Key features of diet-induced obesity are visceral fat deposition, macrophage 
infiltration and inflammation that can lead to metabolic disorders. This study examined 
the effects of BARD in preventing obesity and inflammation in the visceral fat of mice 
fed high-fat diet. Male C57BL/6J mice were fed a HFD, a LFD or a HFD/BARD for 
21 weeks. BARD at dose of 10 mg/kg body weight was administered orally in drinking 




epididymal adipose tissue. Morphological results demonstrate that HFD fed mice 
administered BARD had smaller adipocytes and fewer macrophages present in 
epididymal adipose tissue than HFD group. Furthermore, BARD administration reduced 
the inflammatory profile in this tissue by increasing the expression of nuclear factor of 
kappa-light-polypeptide gene enhancer in B-cells inhibitor, alpha (IκB-α) protein and 
decreasing the protein expression of tumour necrosis factor alpha (TNF-α). BARD also 
prevented oxidative stress reflected by a reduction in stress activated proteins, including 
STAT3, Akt, ERK and JNK. BARD administration activated the sympathetic nervous 
system in epididymal adipose tissue assessed by the increased synthesis of TH and 
UCP2. The expression of inflammatory and sympathetic nervous system proteins in 
BARD mice fed a HFD was equivalent to that of the LFD control mice, indicating the 
anti-inflammatory and anti-obesity properties of this drug. In conclusion, the oral 
administration of BARD in HFD mice prevented fat deposition, inflammation and 
oxidative stress, and improved sympathetic activity in visceral fat. This study suggests a 
potential therapeutic role of BARD in preventing the development of obesity (Chapter 
2).  
1.5.2 BARD Prevents Pathology in Mesenteric Adipose Tissue of High-Fat Diet-
Fed Mice 
Mesenteric fat belongs to visceral fat. An increased deposition of mesenteric fat 
contributes to obesity associated complications such as type 2 diabetes and 
cardiovascular diseases. We have investigated the specific effects of  BARD on 
mesenteric adipose tissue of mice fed a HFD. Male C57BL/6J mice were administered 
oral BARD during HFD feeding (HFD/BARD), or only fed a HFD, or fed a LFD for 21 
weeks. Histology and immunohistochemistry were used to analyse mesenteric 




inflammatory, oxidative stress and energy expenditure proteins. Supplementation of 
drinking water with BARD prevented mesenteric fat deposition, as determined by a 
reduction in large adipocytes. BARD prevented inflammation as there were fewer 
inflammatory macrophages and reduced pro-inflammatory cytokines (IL-1β and TNF-
α). BARD reduced the activation of ERK and Akt, suggesting an anti-oxidative stress 
effect. BARD upregulates energy expenditure biomarkers, judged by the increased 
activity of TH and AMPK, and increased expression of PGC-1α, and UCP2 protein. 
Overall, BARD induces preventive effect in HFD mice through regulation of mesenteric 
adipose tissue (Chapter 3). 
1.5.3 BARD Prevents Pathology in Brown Adipose Tissue and the Brainstem of 
High-Fat Diet-Fed Mice 
Obesity results in changes in brown adipose tissue morphology, leading to fat 
deposition, inflammation, and alterations in sympathetic nerve activity. BARD has been 
extensively studied for the treatment of chronic diseases. We present for the first time 
the effects of oral BARD treatment on brown adipose tissue morphology and associated 
changes in the brainstem. Three groups (n = 7) of C57BL/6J mice were fed either a 
HFD, a HFD supplemented with BARD (HFD/BARD), or a LFD for 21 weeks. 
Interscapular brown adipose tissue, VLM and DVC in the brainstem, were collected for 
analysis by histology, immunohistochemistry and Western blot. BARD prevented fat 
deposition in brown adipose tissue, demonstrated by the decreased accumulation of 
lipid droplets. When administered BARD, HFD mice had lower numbers of F4/80 and 
CD11c macrophages in the brown adipose tissue with an increased proportion of 
CD206 macrophages, suggesting an anti-inflammatory effect. BARD increased 
phosphorylation of TH in brown adipose tissue and the VLM. In the VLM, BARD 




BARD prevented fat deposition and inflammation in brown adipose tissue, and 
stimulated sympathetic nerve activity (Chapter 4). 
1.5.4 BARD Prevents Pathology in Colon of High-Fat Diet-Fed Mice 
Obesity induces chronic low-grade inflammation, which increases the risk of colon 
cancer. We investigated the preventive effects of on HFD-induced inflammation in 
mouse colon. Male C57BL/6J mice (n = 7) were fed a HFD (HFD group), HFD plus 
BARD (10 mg/kg) in drinking water (HFD/BARD group), or normal lab chow diet 
(LFD group) for 21 weeks. BARD reduced colon thickness and decreased colon weight 
per length. This was associated with the increased colon crypt depths and goblet cells 
per crypt. BARD reduced F4/80 and CD11c but increased CD206 and IL-10, indicating 
an anti-inflammatory effect. BARD prevented an increase of the intracellular 
inflammatory biomarkers (NF-қB, p NF-қB, IL-6, TNF- α) and cell proliferation 
markers (Cox2 and Ki67). BARD prevented fat deposition in the colon wall and 
prevented the microbial population changes. Overall, the preventive effects of BARD 
on colon inflammation in HFD fed mice through its regulation of macrophages, NF-қB, 
cytokines, Cox2 and Ki67, fat deposition and microflora are reported in (Chapter 5).  
1.5.5 Summary 
Overall, oral BARD is effective for the prevention of HFD-induced pathologies in 
the colon-brainstem-adipose tissue axis of HFD-fed C57BL/6J mice. The mechanisms 
include the suppression of fat deposition, inflammation, oxidative stress and 
improvement of energy expenditure. BARD administration reduced fat deposition in 
epididymal adipose tissue (Chapter 2), mesenteric adipose tissue (Chapter 3), brown 




BARD also had anti-inflammatory effects in adipose tissues and the colon, as 
assessed by reduction of F4/80 and CD11c positive inflammatory macrophages 
(Chapter 2, 3, 4 and 5), TNF-α (Chapter 2 and 3), IL-1β (Chapter 3 and 5), IL-6 
(Chapter 5), NF-қB (Chapter 2 and 5), COX2 (Chapter 5) and the increase of anti-
inflammatory components including M2 CD206 positive macrophages (Chapter 3, 4 
and 5), and IL-10 (Chapter 5). Furthermore, BARD increased the expression of 
Bacteroides-Prevotella strain while it reduced Bifidobacterium and Lactobacillus strain 
(Chapter 5). This demonstrates the potent anti-inflammatory effect of BARD.  
BARD reduced the expression of the stress-activated proteins including ERK, JNK, 
STAT3, Akt in epididymal fat (Chapter 2), and ERK and Akt phosphorylation in 
mesenteric adipose tissue (Chapter 3). In the colon (Chapter 5), BARD improved colon 
morphology as shown by the increase in colon crypt length and increased number of 
goblet cells per crypt. Interestingly, BARD reduced epithelial proliferating Ki67 cells, 
suggesting anti-proliferative effect. Altogether, this project provides evidence for the 
preventive effect of BARD in HFD-induced pathology in the gut-brain-adipose axis, 
thus suggesting its potential in the prevention of obesity-associated complications.  
Finally, BARD enhances mitochondrial energy metabolism in the WAT-brainstem 
axis, through increased expression of UCP2 in epididymal fat and mesenteric fat 
(Chapter 2 and 3), PGC-1α in mesenteric fat and the brainstem VLM (Chapter 3 and 4), 
and β3-AR in the brainstem (Chapter 4). Interestingly, BARD increased the activity of 
the rate limiting enzyme (tyrosine hydroxylase or TH) in all WAT (Chapter 2 and 3), 
brown adipose tissue (Chapter 4) and the brainstem VLM (Chapter 4), demonstrating an 
important role of noradrenergic innervation in the control of energy expenditure in 





CHAPTER TWO  
Effects of Bardoxolone Methyl on Fat Deposition, Inflammation, 
Oxidative Stress and Energy Expenditure in the Epididymal Adipose 
Tissue of Mice Fed a HFD 
 
Reprinted from Chemico-Biological Interactions, 229, Dinh CHL, Szabo A, Camer D, 
Yu Y, Wang H, Huang X-F.  prevents fat deposition and inflammation in the visceral 
fat of mice fed a high-fat diet, 1-8, Copyright (2015), with permission from Elsevier.  
 

































CHAPTER THREE  
Effects of Bardoxolone Methyl on Fat Deposition, Inflammation, 
Oxidative Stress and Energy Expenditure in the Mesenteric Adipose 
Tissue of Mice Fed a HFD 
 
Reprinted from The Scientific World Journal, 2015 (15), Dinh CHL, Szabo A, Yu Y, 
Camer D, Wang H, Huang X-F,   prevents mesenteric fat deposition and inflammation 
in high-fat diet mice, Copyright (2015), with permission from Creative Commons 
Attribution License. 
 





































































CHAPTER FOUR  
Effects of Bardoxolone Methyl on Fat Deposition and Inflammation in 
Brown Adipose Tissue and Sympathetic Activity in Mice  Fed a HFD 
 
Reprinted from Nutrients, 7(6), Dinh C, Szabo A, Yu Y, Camer D, Zhang Q, Wang H, 
Huang X-F, BARD prevents fat deposition and inflammation in brown adipose tissue 
and enhances sympathetic activity in mice fed a high-fat diet,  4705-4723, Copyright 
(2015), with permission from MDPI. 
  

















































































CHAPTER FIVE  
Effects of Bardoxolone Methyl on Colon Inflammation in Mice  Fed a HFD 
 
Accepted and published in the Journal of Histochemistry and Cytochemistry, 
manuscript ID: JHC-15-0160.R1.  
 
Dinh CH, Yu Y, Szabo A et al. Bardoxolone Methyl Prevents High-Fat Diet-Induced 
Colon Inflammation in Mice. The journal of histochemistry and cytochemistry : official 
journal of the Histochemistry Society 2016; 64:237-255. 
 
 






CHAPTER SIX  
6.1 OVERALL DISCUSSION AND CONCLUSIONS 
This chapter will provide a general discussion and conclusions of the PhD research 
undertaken. The main findings of this thesis are summarised in Table 6.1. Detailed 
discussion of each study has been included in the Discussion sections at the end of 
Chapters 2-5, while overall discussion of the findings is summarised in section 6.1.1. 
The potential mechanism of BARD in this project has been proposed in section 6.1.2. 
Based on the existing body of knowledge and the research outcomes of the present 
project, recommendations for future research will be discussed and summarised in 










Fat deposition (compared with HFD control)  
Enlarged adipocytes in epididymal adipose tissue ↓ 
Small adipocytes in epididymal adipose tissue ↑ 
Enlarged adipocytes in mesenteric adipose tissue ↓ 
Small adipocytes in mesenteric adipose tissue ↑ 
Lipid area in brown adipose tissue ↓ 
Lipid droplet area in brown adipose tissue ↓ 
Lipid area in colon ↓ 
Inflammatory markers (compared with HFD control)  
Infiltrating F4/80 macrophages in epididymal adipose tissue ↓ 
Infiltrating F4/80 macrophages in mesenteric adipose tissue ↓ 
CD11c macrophages in mesenteric adipose tissue ↓ 
CD206 macrophages in mesenteric adipose tissue ↑ 
Infiltrating F4/80 macrophages in brown adipose tissue ↓ 
CD11c macrophages in brown adipose tissue  ↓ 
CD206 macrophages in brown adipose tissue ↑ 
Infiltrating F4/80 macrophages in colon ↓ 
CD11c macrophages in colon ↓ 
CD206 macrophages in colon ↑ 
TNF-α protein in epididymal adipose tissue ↓ 
IқB-α protein in epididymal adipose tissue ↑ 
TNF-α protein in mesenteric adipose tissue ↓ 
IқB-α protein in mesenteric adipose tissue NSC 
IL-1β protein in mesenteric adipose tissue ↓ 
TNF-α protein in colon ↓ 
IL-1β protein in colon ↓ 
IL-6 protein in colon ↓ 
NF-қB protein in colon ↓ 
Phosphorylated NF-қB protein in colon ↓ 
Cox2 protein in colon ↓ 
Ki67 proliferating cells in colon ↓ 
Colon crypt length ↑ 
Goblet cells per colon crypt ↑ 
DNA expression of Bacteroides-Prevotella spp. strain in colon ↑ 
DNA expression of Bifidobacterium sp. strain in colon ↓ 
DNA expression of Lactobacillus spp. strain in colon ↓ 
Oxidative stress (compared with HFD)  
Akt protein in epididymal adipose tissue ↓ 
STAT3 protein in epididymal adipose tissue ↓ 
ERK protein in epididymal adipose tissue ↓ 
JNK protein epididymal adipose tissue ↓ 
Phosphorylated Akt protein in mesenteric adipose tissue ↓ 
Phosphorylated STAT3 protein in mesenteric adipose tissue NSC 
Phosphorylated ERK protein in mesenteric adipose tissue ↓ 
Phosphorylated JNK protein in mesenteric adipose tissue NSC 
Energy expenditure (compared with HFD control)  
Phosphorylated TH protein in epididymal adipose tissue ↑ 
β3-AR protein in epididymal adipose tissue NSC 
UCP2 protein in epididymal adipose tissue ↑ 
Phosphorylated TH protein in mesenteric adipose tissue ↑ 







UCP2 protein in mesenteric adipose tissue ↑ 
PGC-1α protein in mesenteric adipose tissue ↑ 
Phosphorylated AMPK protein in mesenteric adipose tissue ↑ 
Phosphorylated TH protein in brown adipose tissue ↑ 
β3-AR protein in brown adipose tissue NSC 
UCP1 protein in brown adipose tissue NSC 
PGC-1α protein in brown adipose tissue NSC 
Phosphorylated TH protein in the brainstem VLM ↑ 
β3-AR protein in the brainstem VLM ↑ 
UCP2 protein in the brainstem VLM NSC 
PGC-1α protein in the brainstem VLM ↑ 
Phosphorylated TH protein in the brainstem DVC NSC 
β3-AR protein in the brainstem DVC NSC 
UCP2 protein in the brainstem DVC  NSC 
PGC-1α protein in the brainstem DVC NSC 
Abbreviations: AMPK: AMP-activated protein kinase; Akt: protein kinase B; BARD: 
bardoxolone methyl; β3-AR: beta 3-adrenergic receptor; CD11c: marker of M1 
macrophage phenotype; CD206: marker of M2 macrophage phenotype; Cox2: 
cyclooxygenase 2; DVC: dorsal vagal complex; ERK: extracellular signal-regulated 
kinase; F4/80: marker of total macrophage;  IL-1β: interleukin 1 beta; IL-6: interleukin 
6; IL-10: interleukin 10; JNK:  c-Jun N-terminal kinase; Ki67: nuclear antigen Ki67; 
NF-қB: nuclear factor-κ light-chain enhancer of activated B cells; NSC: no significant 
change. PGC-1α: peroxisome proliferator-activated receptor gamma coactivator-1α; 
STAT3: signal transducer and activator of transcription 3; TH: tyrosine hydroxylase; 
TNF-α: tumour necrosis factor alpha; UCP2: uncoupling protein 2; VLM: ventrolateral 
medulla. Significant change, either increase (↑) or reduce (↓) compared with HFD 
control when p < 0.05.  
6.1.1 Overall Discussion and Findings 
In Chapter 2, the preventive effects of BARD in HFD-induced pathology in 
epididymal adipose tissue has been observed. BARD reduced the deposition of fat in 
this tissue as per the decrease in adipocyte size, and also increased the number of small 
adipocytes. BARD reduced inflammation in epididymal adipose tissue as determined by 
the reduction of infiltrating macrophages (F4/80), inflammatory cytokine TNF-α, and 
increase in anti-inflammatory marker Iқ-Bα. Additionally, BARD reduced the 
expression of total stress-activated proteins (Akt, STAT3, JNK and ERK), reflecting the 
potential anti-oxidative stress effect of BARD through regulating oxidative stress 
peptides. It was found that BARD activates sympathetic nerve activity in epididymal 




marker) and mitochondrial uncoupling (UCP2). Overall, BARD prevented fat 
deposition, inflammation and oxidative stress, and improved energy expenditure in 
epididymal adipose tissue of HFD mice.  
In Chapter 3, I investigated the effects of BARD on HFD-induced molecular changes 
in mesenteric adipose tissue through assessing markers of fat deposition, inflammation, 
oxidative stress, and energy expenditure. BARD reduced fat deposition (by reduction of 
adipocyte size), pro-inflammatory cytokines and the number of F4/80 and CD11c 
macrophages while it enhanced the density of CD206 macrophages. Interestingly, there 
was the decreased levels of phospho-Akt and ERK proteins in mesenteric adipose tissue 
of HFD mice suggesting that BARD can prevent oxidative stress, which results from the 
enhanced activation of stress-activated kinases. The data support the concept that HFD-
induced activation of stress-activated kinases in WAT and BARD would be a 
prospective drug for the prevention of oxidative stress in obesity. Similar effect has 
been found in the transgenic adenocarinoma of the mouse prostate model (n = 7) treated 
with BARD for 20 weeks, which significantly reduced phospho-Akt protein compared 
with the control group (Gao et al., 2011).  Considering the decreased level of total 
stress-activated proteins in epididymal adipose tissue under chronic treatment in 
Chapter 2, the mechanism of BARD on oxidative stress regulation in HFD-fed mice 
remains to be established. Otherwise, this project implicates the importance of both 
protein substrate and phosphorylated sinnalling molecular changes in chronic study.  
Moreover, an increase of energy expenditure proteins was observed in mesenteric fat 
with BARD treatment. This includes the increased mitochondrial activity (UCP2, PGC-
1α), and AMPK. Of note is the increase of TH activation in mesenteric fat implicates an 
increase of sympathetic outflow to WAT. Along with the results from epididymal 




Chapter 2 and 3 has concluded that in WAT, BARD prevented lipid accumulation 
due to HFD which leads to adipocyte enlargement in epididymal and mesenteric 
adipose tissue. Modulation of immune cells (macrophages), inflammatory signalling 
and pro-inflammatory cytokines are important properties of BARD in the prevention of 
HFD-induced inflammatory progression in WAT. BARD also increased molecular 
mechanism expressing energy expenditure proteins in WAT including mitochondrial 
uncoupling and mitochondrial biogenesis. Both epididymal and mesenteric fat had 
increased TH expression, a marker of sympathetic nerve activity, indicating a 
stimulatory effect of BARD on noradrenergic nerve fibres in WAT. Decreased white fat 
cell thermogenesis has been found in obese men and women, which is associated with 
reduction of whole body energy expenditure and increased body mass index (Böttcher 
and Fürst, 1997). These data, therefore, implicate the enhancing effect of BARD on 
WAT thermogenesis, which likely supports for obesity prevention.  
In Chapter 4, I investigated the effects of BARD on HFD-induced pathology in 
brown adipose tissue and the brainstem. I observed WAT-like adipocytes in brown 
adipose tissue of HFD mice assessed by increased lipid area and size of lipid droplets, 
which was reversed by BARD. Previously, olanzapine-induced overweight rats have 
reduced number of brown adipocytes, which is associated with decreased thermogenesis 
and  the development of obesity  (Zhang et al., 2014). Interestingly, BARD enhanced 
TH activation with no significant changes in protein expression of UCP1, β3-AR and 
PGC-1α, suggesting enhanced brown adipose tissue thermogenic capacity through 
noradrenergic nerve activation, which is independent of heat production from UCP1. 
Moreover, I found a reduction of total (F4/80) and M1 macrophage phenotype and 
increased anti-inflammatory macrophage phenotype CD206 in brown adipose tissue in 




part of the inflammatory state of mice fed a HFD and a cafeteria diet (Sampey et al., 
2011). A mouse study has shown that M2 macrophages are involved in brown adipose 
tissue thermogenesis (Nguyen et al., 2011). Overall, this study implicates the potential 
of BARD in restoring the active state of brown adipose tissue, which may be beneficial 
for obesity resistance.  
Also in Chapter 4, this project has demonstrated for the first time the enhancement 
by BARD of energy metabolism in the brainstem of HFD mice. Specifically, BARD 
affects the VLM region but not the DVC, through the upregulation of biomarkers for 
energy expenditure (TH, β3-AR and PGC-1α). A previous report has suggested the 
involvement of the VLM region  in the induction of sympathetic outflow to brown 
adipose tissue  (Madden et al., 2013). There are also reports on the participation of DVC 
in satiation (Berthoud et al., 2006, Grill, 2006, Grill and Hayes, 2009). This indicates an 
important role of VLM in the induction of autonomic nerves, and may be a site of action 
for BARD. The increase of β3-AR and PGC-1α in the VLM in response to BARD also 
demonstrates that BARD induced energy homeostasis in brainstem through adrenergic 
receptor activation and mitochondrial biogenesis. Moreover, the brainstem data are in 
agreement with a recent study showing that HFD induces dysfunction of autonomic 
nerve activity in the brainstem, which may drive the development of obesity (Bhagat et 
al., 2015). Together with the activation of noradrenergic nerve fibres and energy 
expenditure proteins in WAT (Chapter 2 and 3), these findings suggest that BARD may 
act on thermogenesis through stimulating sympathetic outflow to brown adipose tissue 
and WAT, and the brainstem VLM as an autonomic centre for the control of energy 
homeostasis. Activation of the sympathetic nervous system is associated with weight 
loss, and reduction of energy intake (Bobbioni-Harsch et al., 2004). Altogether, present 




against diet-induced pathology in the brown adipose tissue and brainstem which maybe 
the mechanisms for obesity resistance.  
In Chapter 5, the therapeutic effect of BARD on mouse colon was investigated. 
BARD decreased fat deposition in the colon suggesting effects on fat storage, similar to 
epididymal adipose tissue (Chapter 2), mesenteric fat (Chapter 3), and brown adipose 
tissue (Chapter 4). Interestingly, BARD reduced colon thickness, increased colon crypt 
depth and increased goblet cells per crypt in HFD mice compared to HFD and LFD 
control. Therefore, while HFD affects colon crypts and morphology, BARD can prevent 
these changes so that they resemble those of LFD mice. BARD reduced the expression 
of the inflammatory markers F4/80 and CD11c, and conversely increased expression the 
anti-inflammatory markers CD206 and IL-10. BARD prevented the HFD diet induced 
increase of pro-inflammatory molecules and markers of proliferating cells, including 
NF-қB, IL-6, IL-1β, TNF-α, Cox2 and Ki67. It has been shown that M1 macrophages 
can disrupt the epithelial barrier, leading to intestinal inflammation in inflammation 
bowel disease (Lissner et al., 2015). BARD lowered M1 expression in the colon of HFD 
mice, suggesting a protective role in mouse colon. Moreover, the protective effect of 
BARD in HFD mice was further indicated through its effects on gut microbiota, with 
increased Bacteroides-Prevotella spp. strain and reduced Bifidobacterium spp., and 
Lactobacillus spp. strains. For the first time, this PhD project has shown a preventive 
effect of BARD on colon inflammation in HFD-fed mice, through its regulation of fat 
deposition, microbiota, macrophages, NF-қB, pro-inflammatory cytokines, Cox2 and 
Ki67. Several evidences have demonstrated intestinal inflammation in mouse models 
when they were on HFD for over 20 weeks (Axling et al., 2012, Shen et al., 2014). The 




present study are signals for the potential of this compound in preventing HFD-induced 
pathology in the gut.  
Dietary supplementation of oral BARD is effective in the prevention of diet-induced 
obesity and pathology in brain-stem, colon, WAT and brown adipose tissue of HFD-fed 
mice. Previously, similar effects including the induction of weight loss, anti-
inflammation, and reduction of lipid accumulation, tissue damage have been observed 
in liver and kidney of HFD-fed C57BL/6 mice and diabetic rat model when treated with 
BARD analogs (RTA405) at 10mg/kg dosage (Chin et al., 2013). The present results 
using HFD mice are consistent with clinical studies showing that normal weight and 
obese men have differing metabolic and inflammatory profiles (Schwander et al., 2014), 
and that BARD can prevent HFD-induced changes of such factors. Clinical studies have 
shown that diet-induced weight loss reduces inflammatory cytokines (IL-6) and 
metabolic syndrome (reduction of body mass index, cholesterol and triglyceride) in 
obese individuals (Tajik et al., 2013). BARD targets many inflammatory and oxidative 
stress markers in the WAT, brown adipose tissue and colon in HFD mice implicating its 
therapeutic functions in obesity-related pathology. The reduced fat deposition reported 
in Chapter 2-5 indicates that BARD induces an anti-obesity effect involving the 
regulation of body fat distribution. Increased expression of TH and energy expenditure 
proteins in WAT, brown adipose tissue and the brainstem suggest the potential role of 
BARD in the control of energy balance.  
Finally, there was no side effect or mortality oberseved in the experimental mice of 
these studies, which is associated with previous studies showing the protective effect of 
BARD and its analogs against toxicity in lung cancer mouse model, and well-tolerated 




6.1.2. Proposed Mechanisms of BARD in Prevention of Diet-Induced Obesity 
Based upon the findings of this project the effect of BARD on the gut-brain-adipose 










In WAT: BARD prevented HFD-pathology in WAT through (1) Reducing the overload 
of lipid from HFD to mesenteric and epididymal fat depots that leads to adipocyte 
enlargement and fat deposition in these tissues (2) Suppressing oxidative stress through 
reducing activity of stress-activated kinases (3) Reducing progressive inflammation 
state as per suppression of macrophage infiltration, pro-inflammatory cytokine 
production and activation of inflammatory signalling NF-қB.  
In brown adipose tissue: BARD increased the active state of brown adipose tissue 
through (1) Reduction of fat deposition, which is associated with reduction of 
macrophage infiltration in this tissue (2) Enhancement of brown adipose tissue 
thermogenic capacity through noradrenergic nerve activation.  
In the brainstem: BARD increased energy expenditure through (1) stimulating 
noradrenergic nerve fibres, which enhances sympathetic outflow to brown adipose 
tissue and WAT (2) Activating adrenergic receptor (3) Activating mitochondrial 
biogenesis.  
In colon: BARD prevented HFD-induced colon inflammation through (1) Suppressing 
infiltration and invasion of inflammatory macrophage (2) Reducing pro-inflammatory 
cytokine production and NF-қB signalling activity (3) Reducing Cox2 expression and 
Ki67 proliferating cells (4) Suppressing fat deposition to colon (5) Reducing the 
invasion of bacterial strains which promotes inflammation (6) Inducing IL-10.  
 
Abbreviations: BARD: bardoxolone methyl; BAT: brown adipose tissue; Cox2: 
cyclooxygenase 2; HFD: high-fat diet, IL-10: interleukin 10; NF-қB: nuclear factor-κ 
light-chain enhancer of activated B cells; Ki67: nuclear antigen Ki67; TH: tyrosine 






6.1.3. Recommendations for Future Research 
The aim of this PhD project was to investigate the preventive effect of BARD on 
diet-induced obesity focussing on prevention of pathologies in tissues. Through a series 
of studies of the gut-brain-adipose axis, several observations were made that may assist 
future research of obesity.  
1. BARD modulates lipid droplets size and adipocytes size, which lilkely protects fat 
cells from stress, adiposity, and thus indirectly prevents obesity (Chapter 2, 3, 4 and 5). 
In obese humans increased adipocyte size is linked with obesity-associated metabolic 
disorders (Stern et al., 1972). Future research on body fat metabolism and signalling 
will be interesting targets for obesity management.  
2. This thesis show that BARD reduces inflammation associated with the development 
of obesity. The exact sites of BARD effect on inflammation are to reduce pro-
inflammatory cytokines such as TNF-α, IL-1β and IL-6 and to regulate markers 
associated with inflammatory response such as NF-κB signalling molecules, 
intracellular signalling molecules while it increases anti-inflammatory cytokines such as 
IL-10 found in visceral white adipose tissue, brown adipose tissue or colon of thesis. 
Multiple targets of BARD in this thesis may relate to its primary action on nuclear 
factor like 2 (Nrf2), which binds to anti-oxidant response elements leading to its 
modulation on anti-oxidant genes and inflammatory process in a variety of organs 
(Camer et al., 2014, Reisman et al., 2012). Future research could investigate many other 
cytokines (eg IL-8, IL-4, IL-13, IL-18, IL-37) (McArdle et al., 2013, Ballak et al., 2014) 






3. BARD induces anti-inflammatory effect in multiple organs. Inflammation in obesity 
is associated with tissue breakdown leading to the delay of wound healing process 
(Pence, 2012), therefore, BARD would be an obesity-associated wound care. However, 
further research to examine the effects of BARD on infection and wound healing 
process is ascertain. Method could be conducted as per previous evidence showing that 
oleanolic acid triterpenoid induced anti-inflammatory effects and promoted wound 
healing process in carrageenan-induced paw edema in rat (Gupta et al., 1969). Further 
research would be a test of collagen deposition and tensile strength of fibrous tissue, 
which reflects the speed of wound healing process, in obesity-induced mouse model 
treated with BARD. 
4. BARD is efficacious for treatment and prevention of many diseases-associated 
inflammation due to its high concentration in tissues and treating targets. For example, 
BARD concentration in tumor of 4T1 breast cancer bearing mice was >3µmol/L 
compared with the required in vitro concentration at 500 nmol/L (Ling et al., 2007). In 
my study, the alterations of drug targets in the experimental tissues reflects the signicant 
fluctuations of this compound’s concentration among these tissues. Further study on 
pharmacokinetics of BARD in obesity will help to adjust its dose for maximal and 
efficacious concentrations in each tissue and therefore to minimise clinical failure and 
drug resistance. 
5. Modulation of BARD on gut microbiota is another anti-inflammatory mechanism in 
vivo of BARD in this thesis. Since gut microbiota are involved in intestinal 
permeability, and development of inflammation, and metabolic disorders in HFD-fed 
mice (Fernández-Sánchez et al., 2011). Up-to-date, microbiome gene expression profile 
associated with BARD treatment has not been established in obesity research. Such 




microbiome in obese humans and on the connection between microbiome and other 
obesity-related factors such as triglyceride clearance or fat absorption.  
6. Metabolism of action on energy balance is an important factor for the control of body 
weight and HFD-induced obesity by BARD (Chapter 2, 3, 4). The compound promotes 
energy expenditure through the activation of noradrenergic nerve fibers (tyrosine 
hydroxylase) in the sympathetic nervous system from the brainstem to white and brown 
adipose tissue, which is associated with the enhancement of many energy expenditure 
proteins including uncoupling protein, PGC-α, and AMPK. BARD is attributed to 
increased oxygene consumption in HFD mice (Saha et al., 2010). Action on energy 
metabolism implicates BARD as a thermogenic agent for obesity prevention and 
treatment. Future experiments to assess whole-body sympathetic nervous activity using 
cold or norepinephrine challenges will help to determine maximal thermogenic capacity 
of each experimental groups with or without BARD treatment. 
7. This project performed in a chronic study with multiple comparison between the mice 
with/without BARD treatment. Although the study does not include data on weight loss 
or other toxicities (general conditions, food intake, movement) the research shows that 
BARD prevented body weight gain in HFD-fed mice without side effects or death. 
Regarding potential adverse effects of BARD, a report has shown that BARD may 
induce toxic metabolites via activating renal endothelin pathway, which has been 
indicated for heart failure and death in type 2 diabetic patients with stage 4 chronic 
kidney disease (Chin et al., 2014). Therefore, I recommend that BARD should not be 
used in patients with advanced chronic kidney disease. Otherwise, BARD and its 
analogs have been shown to be efficicous, well-tolerated with minimal toxicity in both 
humans and animal models (monkeys, rats and mice) (Chin et al., 2013, Hong et al., 




effects of BARD on heart and kidney of HFD-fed mice (Camer et al., 2016), however, 
further studies on endothelin pathway and related mechanism in each tissue have been 
recommended. Additional studies on clinical biochemistry are necessary to evaluate the 
safety margin of oral BARD. Measurement of apoptotic biomarkers in various organ 
tissues could be conducted, for example. More safety profile of BARD in clinical study 
is important to address health effects in patients with advanced chronic kidney diseases.  
8. The preventive effects of BARD on body weight gain and its mechanism of actions 
on gut-brain-adipose axis suggest that this compound could be used to prevent weight 
regain in obese patients who already have weight loss program and suggest the 
possibility of this compound as anti-obesity therapeutic. 
6.1.2 Conclusions 
BARD at dose of 10mg/kg body weight corrected various pathologies of obesity 
within the brainstem-colon-adipose tissue axis, indicating preventive effects of this 
compound on obesity-associated pathology. BARD decreased fat deposition in 
epididymal and mesenteric adipose tissue, and brown adipose tissue through reducing 
adipocyte size and lipid area, leading to a shift towards smaller adipocyte populations. 
BARD induced anti-oxidative stress and anti-inflammatory effects through the 
suppression of stress-activated molecules, inflammatory macrophages, NF-қB, and pro-
inflammatory cytokines. The effect of BARD on reducing cell proliferation indicates the 
potential of BARD in preventing carcinogenesis and tumorigenesis. BARD promoted 
energy expenditure by activating adrenergic receptor, noradrenergic nerve fibres, 
mitochondrial biogenesis and mitochondrial uncoupling. The results from this PhD 
project have provided insight regarding the therapeutic mechanisms of BARD on 
brainstem-colon-adipose tissue, which may be beneficial for the prevention of 




and upregulation of energy expenditure processes, which contribute to the health 
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